Impact News +++ Milliarden-Deal: Accenture übernimmt Netzwerkanalyse-Spezialisten Ookla (Heise) +++ ZIFF DAVIS Aktie -10,50%

UCB Aktie

>UCB Aktienkurs

250.2 EUR +0.1% (TradegateBSX)

Ask: 250.8 EUR / 25 Stück

Bid: 250.5 EUR / 25 Stück

Tagesumsatz: 429 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

UCB Aktie über LYNX handeln

Intraday

1 Jahr

>UCB Performance

1 Woche: -7,4%

1 Monat: -4,1%

3 Monate: +3,0%

6 Monate: +26,4%

1 Jahr: +36,7%

laufendes Jahr: +5,6%

>UCB Aktie

Name:

UCB S.A.

Land:

Belgien

Sektor:

Gesundheit

ISIN/ Wkn:

BE0003739530 / 852738

Symbol/ Ticker:

UNC (Frankfurt)

Kürzel:

FRA:UNC, ETR:UNC, UNC:GR

Index:

Webseite:

https://www.ucb.com/

Profil:

UCB SA is a multinational biopharmaceutical company headquartered in Brussels, Belgium, founded in 1928 by Emmanuel Janssen. It specializes in developing innovative medicines for severe neurological a..
>Volltext..

Marktkapitalisierung:

47859.16 Mio. EUR

Unternehmenswert:

47634.52 Mio. EUR

Umsatz:

7695.76 Mio. EUR

EBITDA:

2620.59 Mio. EUR

Nettogewinn:

1548.89 Mio. EUR

Gewinn je Aktie:

8.15 EUR

Schulden:

2231.88 Mio. EUR

Liquide Mittel:

2237.84 Mio. EUR

Operativer Cashflow:

2150.36 Mio. EUR

Bargeldquote:

0.56

Umsatzwachstum:

25.83%

Gewinnwachstum:

46.29%

Dividende je Aktie:

1.39 EUR

Dividendenrendite:

0.39%

Dividendenschätzung:

0.39%

Div. Historie:

25.04.25 - 1.39€
26.04.24 - 1.36€

>weitere anzeigen...

Insiderhandel:

Suchwörter:

UCB

Letzte Datenerhebung:

03.03.26

>UCB Kennzahlen

Aktien/ Unternehmen:

Aktien: 190.36 Mio. St.

Frei handelbar: 61.29%

Leerverk. Aktien: 0.53%

Rückkaufquote: 0.25%

Mitarbeiter: 10117

Umsatz/Mitarb.: 0.76 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 17.12%

Bewertung:

KGV: 30.9

KGV lG: 23.56

KUV: 6.24

KBV: 4.34

PEG-Ratio: 0.67

EV/EBITDA: 18.18

Rentabilität:

Bruttomarge: 71.14%

Gewinnmarge: 20.13%

Operative Marge: 25.95%

Managementeffizenz:

Gesamtkaprendite: 8.78%

Eigenkaprendite: 14.91%

>UCB Anleihen

>UCB Peer Group

Gesundheit, Autoimmunerkrankungen

>UCB Chart & Kurs - Tradegate

>UCB News

02.03.26 - 14:31	Best Income Stocks to Buy for March 2nd (Zacks)
	CZNC, UCB and CRI made it to the Zacks Rank #1 (Strong Buy) income stocks list on March 2, 2026....

27.02.26 - 16:18	UCB übertrifft Prognosen im zweiten Halbjahr 2025 – Aktie legt zu (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

26.02.26 - 09:01	UCB Full-year Profit, Sales Jump: Issues Upbeat Outlook (AFX)
	BRUSSELS (dpa-AFX) - UCB SA (UCBJY) on Thursday reported a 46% increase in full-year profit, supported by a 32% rise in sales.Profit before income taxes increased 57% to €1.822 billion from €1.163......

26.02.26 - 08:45	UCB beats profit forecasts but 2026 guidance disappoints (Investing.com)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

26.02.26 - 08:33	UCB SA FY25 EBITDA jumps on Bimzelx surge; margin hit by one-offs (Investing.com)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

26.02.26 - 07:51	UCB SA Non-GAAP EPS of €9.99, revenue of €7.74B; introduces FY26 outlook (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.02.26 - 15:15	Best Income Stocks to Buy for February 12th (Zacks)
	WTBA, UCB and RELX made it to the Zacks Rank #1 (Strong Buy) income stocks list on February 12, 2026....

03.02.26 - 17:30	Best Momentum Stocks to Buy for February 3rd (Zacks)
	CX, UCB and TCBI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 2, 2026....

03.02.26 - 13:45	New Strong Buy Stocks for February 3rd (Zacks)
	UCB, CX, TCBI, LC and KC have been added to the Zacks Rank #1 (Strong Buy) List on February 3, 2026....

03.02.26 - 11:15	Best Income Stocks to Buy for February 3rd (Zacks)
	UCB, BCML and UBSI made it to the Zacks Rank #1 (Strong Buy) income stocks list on February 3, 2026....

16.01.26 - 17:31	Best Momentum Stocks to Buy for Jan. 16 (Zacks)
	UCB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Jan.16, 2026....

16.01.26 - 13:00	New Strong Buy Stocks for January 16th (Zacks)
	REPX, UCB, CRUS, IPGP and SWRAY have been added to the Zacks Rank #1 (Strong Buy) List on Jan.16, 2026....

16.01.26 - 10:45	Best Income Stocks to Buy for Jan. 16 (Zacks)
	REPX and UCB made it to the Zacks Rank #1 (Strong Buy) income stocks list on Jan.16, 2026....

11.12.25 - 08:03	Lee′s Pharmaceutical Holdings Limited Acquires Staccato® One Breath Technology® Platform and Assets, Driving Pipeline Expansion and Advancing Global Partnership with UCB Through Acquired Rights (PR Newswire)
	Acquisition of Staccato® One Breath Technology®, a proprietary platform technology with broad therapeutic potential Synergistic and complementary to Lee's Pharm's existing products pipeline, and Acquisition of rights as licensor and manufacturer of Staccato® alprazolam under a global......

09.12.25 - 14:06	Lee′s Pharmaceutical Holdings Limited Acquires Staccato® One Breath Technology® Platform and Assets, Driving Pipeline Expansion and Advancing Global Partnership with UCB Through Acquired Rights (PR Newswire)
	Acquisition of Staccato® One Breath Technology®, a proprietary platform technology with broad therapeutic potential Synergistic and complementary to Lee's Pharm's existing products pipeline, and Acquisition of rights as licensor and manufacturer of Staccato® alprazolam under a global......

08.12.25 - 13:03	UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder (PR Newswire)
	Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in countable motor seizure frequency (CMSF) compared with placebo1 Holistic Improvement: two of the three key secondary endpoints showed significantly greater......

08.12.25 - 07:48	UCB meldet positive Phase-3-Ergebnisse für Fenfluramin bei CDKL5-Mangelsyndrom/n (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

08.12.25 - 07:42	Corporate News: UCB (EQS)
	UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder...

08.12.25 - 07:36	UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder (PR Newswire)
	Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in countable motor seizure frequency (CMSF) compared with placebo1 Holistic benefit: secondary endpoints showed significant and clinically meaningful improvements......

05.12.25 - 11:24	UCB Rises as Demand for Skin Disease Drug Spurs Outlook Boost (Bloomberg)
	UCB SA shares surged the most in more than nine weeks after the Belgian biopharmaceutical company upgraded its outlook for the year, reassuring investors about the demand for one of its most important medicines....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Das Übel nährt sich nur von seinesgleichen. Weise Menschen vergalten daher nicht Böses mit Bösem, sondern immer nur mit Gutem und brachten dadurch das Böse zu Fall. - Mohandas

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram